CN1255151C - Compound Longxue scorpion and preparation method thereof - Google Patents
Compound Longxue scorpion and preparation method thereof Download PDFInfo
- Publication number
- CN1255151C CN1255151C CNB031177719A CN03117771A CN1255151C CN 1255151 C CN1255151 C CN 1255151C CN B031177719 A CNB031177719 A CN B031177719A CN 03117771 A CN03117771 A CN 03117771A CN 1255151 C CN1255151 C CN 1255151C
- Authority
- CN
- China
- Prior art keywords
- blood
- drug
- dragon
- radix notoginseng
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 12
- 150000001875 compounds Chemical class 0.000 title abstract description 26
- 241000239226 Scorpiones Species 0.000 title 1
- 239000003814 drug Substances 0.000 claims abstract description 34
- 241000180649 Panax notoginseng Species 0.000 claims abstract description 28
- 235000003143 Panax notoginseng Nutrition 0.000 claims abstract description 28
- 239000000843 powder Substances 0.000 claims abstract description 23
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical compound C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 claims abstract description 12
- 239000002775 capsule Substances 0.000 claims abstract description 4
- 239000007788 liquid Substances 0.000 claims abstract description 3
- 239000003826 tablet Substances 0.000 claims abstract description 3
- 239000009286 sanguis draxonis Substances 0.000 claims description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000003285 pharmacodynamic effect Effects 0.000 claims description 2
- 239000002994 raw material Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 22
- 239000009136 dragon's blood Substances 0.000 abstract description 19
- 229940079593 drug Drugs 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 10
- 230000017531 blood circulation Effects 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 6
- 208000029078 coronary artery disease Diseases 0.000 abstract description 5
- 208000002193 Pain Diseases 0.000 abstract description 4
- 239000000284 extract Substances 0.000 abstract description 4
- 206010002383 Angina Pectoris Diseases 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000002347 injection Methods 0.000 abstract description 2
- 239000007924 injection Substances 0.000 abstract description 2
- 229930182490 saponin Natural products 0.000 abstract description 2
- 150000007949 saponins Chemical class 0.000 abstract description 2
- 235000017709 saponins Nutrition 0.000 abstract description 2
- 231100000027 toxicology Toxicity 0.000 abstract description 2
- 240000004824 Trimezia steyermarkii Species 0.000 abstract 4
- REPVLJRCJUVQFA-UHFFFAOYSA-N (-)-isopinocampheol Natural products C1C(O)C(C)C2C(C)(C)C1C2 REPVLJRCJUVQFA-UHFFFAOYSA-N 0.000 abstract 2
- 229940116229 borneol Drugs 0.000 abstract 2
- CKDOCTFBFTVPSN-UHFFFAOYSA-N borneol Natural products C1CC2(C)C(C)CC1C2(C)C CKDOCTFBFTVPSN-UHFFFAOYSA-N 0.000 abstract 2
- DTGKSKDOIYIVQL-UHFFFAOYSA-N dl-isoborneol Natural products C1CC2(C)C(O)CC1C2(C)C DTGKSKDOIYIVQL-UHFFFAOYSA-N 0.000 abstract 2
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 206010040007 Sense of oppression Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 239000001914 daemonorops spp. extract Substances 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 230000002110 toxicologic effect Effects 0.000 abstract 1
- 241001043298 Croton draco Species 0.000 description 15
- 239000003146 anticoagulant agent Substances 0.000 description 8
- 230000000857 drug effect Effects 0.000 description 8
- 208000007536 Thrombosis Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 230000002537 thrombolytic effect Effects 0.000 description 5
- 230000000302 ischemic effect Effects 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 244000131316 Panax pseudoginseng Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 208000010125 myocardial infarction Diseases 0.000 description 3
- 208000031225 myocardial ischemia Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000630 rising effect Effects 0.000 description 3
- XPCFTKFZXHTYIP-PMACEKPBSA-N Benazepril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 XPCFTKFZXHTYIP-PMACEKPBSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 208000005189 Embolism Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 208000001435 Thromboembolism Diseases 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000006793 arrhythmia Effects 0.000 description 2
- 206010003119 arrhythmia Diseases 0.000 description 2
- 229960004530 benazepril Drugs 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 230000035487 diastolic blood pressure Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 230000036284 oxygen consumption Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 230000035488 systolic blood pressure Effects 0.000 description 2
- 241000746976 Agavaceae Species 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 241001561260 Dracaena cambodiana Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- 235000003181 Panax pseudoginseng Nutrition 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000008899 fufang danshen Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 230000001631 hypertensive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a compound dragon's blood drug and a preparation method thereof. The drug mainly contains dragon's blood, powdered notoginseng and trace borneol. The preparation method comprises the steps that the dragon's blood and the notoginseng as medicinal materials are respectively selected and pulverized to extract effective components, and a dragon's blood powder extract and a powdered notoginseng extract are pulverized and then are mixed; the drug is prepared by adding and mixing a trace borneol powder. The drug can be prepared into capsules, powders, tablets, oral liquid and injections on the basis of the preparation method; the purity of the dragon's blood extract can reach more than 90%, and the total saponins of the notoginseng are larger than 50%. Toxicological experiments, pharmacological experiments and pharmacodynamical experiments conducted by authoritative organizations prove that The present invention has the advantages of no toxic or side effect and use safety, and has the effects of activating blood circulation to dissipate blood stasis, freeing the orifices and stopping pain; the drug is suitable for signs of coronary heart disease, angina pectoris, etc. such as chest impediment, heart pain, oppression in chest, stabbing pain, etc. caused by stagnation of heart blood, and the curative effects of the drug is obviously superior to those of a compound red sage root drug; the drug is twenty-fourth to seventeenth the price of a western drug with the same effects.
Description
Technical field the present invention relates to a kind of Chinese medicine preparation, compound dragon's blood and preparation method.
The background technology cardiovascular disease is important clinically common frdquently encountered disease, has anxious, the characteristics such as change of illness state is fast, mortality rate height of morbidity.Coronary heart disease, hypertensive cardiopathy are that American-European countries is sick kind of painstaking effort tubing of seeing more, and according to the interrelated data statistics, the U.S. had 6,080,000 people to suffer from coronary heart disease in 1988, and about 540,000 people are therefore sick and dead.In China since the fifties in last century, the M ﹠ M of these two kinds of diseases is also rising, wherein Incidence of CHD is 0.6% to 14.29% not wait, ordinary circumstance is that developed regions are higher, remote lower with backward areas, illustrate that this type of disease and people's living standard has certain proportional relationship.Indicating that this type of disease is just becoming a serious killer of China's people's life.
How effectively to prevent and treat this type of disease is one of emphasis of medical circle research always.Medicine on the doctor trained in Western medicine generally is that drug effect is fast, the efficacy of a drug is also more concentrated, but side effect is bigger, and main is to cost an arm and a leg, and general patient can't bear.As the depressor of Western medicine, the market price of benazepril is 7 a yuans/sheet; The thrombolytic medicine is to the 5 yuan/sheet of market price of calix.
The Chinese medicine of existing treatment similar disease is also many, but is to make with crude drug mostly, and active component is lower, and drug effect is slow, the efficacy of a drug a little less than.As FUFANG DANSHEN PIAN is that the former medicated powder of Radix Salviae Miltiorrhizae, Radix Notoginseng and Borneolum Syntheticum mixes after broken, and effective ingredient is very low, and drug effect clinically is slow, and the patient will take heavy dose of tablet just can be effective.
Sanguis Draxonis has another name called Sanguis Draxonis, is Agavaceae plant, and the extract of dracaena cambodiana Pierre is gained the name because of color is blood red.Through the medical research in nearly ten years, the medical usage of Sanguis Draxonis was gradually known for people.It has antithrombotic and forms, reduces whole blood and plasma viscosity and cell pack, accelerates cell electrophoresis speed, and anticoagulant makes the unobstructed effect of blood flow with accelerating platelet electrophoresis speed; Also have effects such as arrhythmia.Yet people also rest in single agent its utilization at present, have hindered the performance of its drug effect.
Chinese medicine preparation---compound dragon's blood and preparation method thereof of the treatment cardiovascular disease that goal of the invention the objective of the invention is to propose that a kind of cost is low, drug effect is high, have no side effect is to overcome the deficiencies in the prior art.
This compound dragon's blood that summary of the invention is proposed by the invention mainly contains Sanguis Draxonis and Radix Notoginseng powder.
It contains Borneolum Syntheticum.The main component of Borneolum Syntheticum is a Borneolum Syntheticum.
The mixed proportion of Sanguis Draxonis and Radix Notoginseng powder is 1: 0.1-0.3, Borneolum Syntheticum trace.
Sanguis Draxonis and Radix Notoginseng powder are the purification thing, and the alcohol soluble substance of Sanguis Draxonis contains 〉=more than 70%, the Radix Notoginseng total arasaponins of Radix Notoginseng powder 〉=40%.
Alcohol soluble substance content 〉=95% of Sanguis Draxonis, the Radix Notoginseng total arasaponins of Radix Notoginseng powder 〉=50%.
Compound longxuejie preparation is tablet, powder, capsule, oral liquid and injection.
The compound dragon's blood preparation method that the present invention proposes is characterized in that it has the following steps:
(1) chooses qualified Folium Dracaenae cambodianae and pseudo-ginseng respectively and pulverize, distinguish effective component extracting;
(2) Sanguis Draxonis and the Radix Notoginseng powder purification thing of purifying are pulverized the back mixing;
(3) will go up step products obtained therefrom packing or add and mix packing behind the micro-Borneolum Syntheticum powder.
The fineness of Sanguis Draxonis and Radix Notoginseng powder is more than 800 orders, reaches nanoscale.
Invention effect Sanguis Draxonis energy anticoagulant is accelerated platelet electrophoresis speed, thereby is made blood flow unimpeded, prevents thrombosis, also has arrhythmia and effects such as hemostasis, antiinflammatory and sterilization; And Radix Notoginseng extract, Radix Notoginseng total arasaponins (PTS) then to the heart and brain organ, to blood vessel and blood pressure, all have positive protection or other to benefit effect to aspects such as platelet aggregations; Borneolum Syntheticum also resists myocardial ischemia, analgesia and sedation.
The present invention is according to the control effect and mechanism of above-mentioned three flavor Chinese medicines, and is reasonably combined, forms based on Sanguis Draxonis, and Radix Notoginseng is auxilliary, and Borneolum Syntheticum is the monarch and his subjects' accessory drugs effect relationship that helps, and allows it work in coordination, to promote mutually, gives full play to the effect of the combination efficacy of a drug.It has following positive effect:
Toxicology, pharmacology and pharmacodynamic experiment through authoritative institution prove that the present invention is without any side effects, and be safe and reliable, drug effect height, and longer duration.It has blood circulation promoting and blood stasis dispelling, and the effect of understand things pain-stopping is applicable to obstruction of qi in the chest and cardialgia due to the stagnation of heart-blood, twinge uncomfortable in chest, angor, does not fixingly move, and goes into Night Watch very, the time or palpitation and uneasiness, syndromes such as coronary heart disease such as purplish tongue, deep pulse, angina pectoris.The medicated powder of nanoscale fineness has strengthened the dispersion and the assimilation effect of medicine greatly, has improved the biological utilisation degree of medicine, further strengthened invigorate blood circulation, hemostasis, analgesic effect.
Curative effect obviously is better than compound Salviae Miltiorrhizae.
Cheap, can be acceptant for extensive patients, the market price that the compound dragon's blood capsule is every only is about 0.3 yuan, only to be equivalent to 1/24th of Western medicine benazepril, supports 1/17th of calix.
To the Chinese medicine herb resource, particularly Sanguis Draxonis resource of exploitation China's abundant, improve the Chinese patent medicine technology content, ensure that people's health has far reaching significance.
It below the specific embodiment part animal experiment example.
Example one
With the Sanguis Draxonis that meets above-mentioned requirements, Radix Notoginseng powder and Borneolum Syntheticum, with 1: 0.137: 0.0076 mixed, wherein the alcohol soluble substance content of Sanguis Draxonis reached 95.6%, and the content of the total saponins in radix notoginseng 51% of Radix Notoginseng powder is ground into the end after the mixing.Thin more good more.With such mixture white mice is carried out acute toxicity test.Way is once to irritate stomach with the dosage of 150 times of normal human body daily doses (6 grams/1000 gram body weight), dissects check after the week, does not find toxic reaction.
Example two
Irritate stomach with the dosage grouping of 15,30 and 60 times of normal human's daily doses respectively with the medicament identical with example one, 26 weeks of continuous irrigation, dissect check, do not see toxic reaction.
Example three
The high, medium and low dosage of compound dragon's blood is used for experimental mouse, shows that all can obviously press down anti-isoproterenol causes Mus ECGST ischemic change (P＜0.01 or 0.05); Obviously increase the dirty coronary flow of normal guinea-pig heart, the normal guinea-pig heart rate that significantly slows down (P＜0.01 or 0.05), obviously the vertical 2 body pituitrins of antagonism brain shrink arteria coronaria effect (P＜0.01 or 0.05).Confirm that this medicine has the effect of the very strong hemopoietic of invigorating blood circulation, minimizing blood viscosity, compare that effect obviously is better than compound Salviae Miltiorrhizae with compound Salviae Miltiorrhizae.
Example four
With the contrast experiment who is used for experimental mouse with the medicine and the compound Salviae Miltiorrhizae of example one identical prescription, prove that the high, medium and low dosage of compound dragon's blood reaches 57.75%, 50.0%, 53.4% respectively at the suppression ratio that suppresses thrombosis (the method for bypass); The arterial thrombus that electricity irritation is formed, the effect of thromboembolism again (P＜0.01 or 0.05) after having more tangible thrombolytic and prevent thrombolytic than compound Salviae Miltiorrhizae.Prove that this medicine has the effect of obvious reduction platelet aggregation.
Example five
High, medium and low dosage of compound dragon's blood and compound recipe ginseng can make acute " blood stasis " rat whole blood viscosity, whole blood reduced viscosity, plasma viscosity, packed cell volume that obvious reduction (P＜0.01 or 0.05) is arranged, and both drug effects are suitable in this test.
Example six
Due to the ligation anesthetized dog arteria coronaria on the myocardial infarction and ischemia model; compound dragon's blood has obvious minimizing myocardial infarct size; high; in; the low dose group myocardial infarct size reduces to 6.7% respectively; 14.2% and 15.9%; be starkly lower than normal saline group (26.3%); and present certain dose-dependence (P＜0.01 or 0.05); be subjected to reagent obviously to suppress the ischemic ST change (P＜0.01) that ligation dog arteria coronaria causes simultaneously; and obviously suppressing the serum creatine kinase (CPK) that ligation dog arteria coronaria causes and the rising (P＜0.01 or 0.05) of lactic acid dehydrogenase (LDH), prompting has obvious protective effect to the injury of myocardium cell.
Example seven
Each dosage group of compound dragon's blood to the maximum rate of change of the left indoor pressure of anesthetized dog (± dp/dt), left indoor pressure (LVP), left ventricular end diastolic presssure (LVEDP), systolic pressure (SP), diastolic pressure (DP), heart rate (HR) there are no significant difference, illustrate to be subjected to reagent not influence anesthetized dog cardiac function under the body situation.
Example eight
High, medium and low dosage of compound dragon's blood and compound recipe ginseng significantly reduce per minute tension time index (TTI * heart rate), and prompting is subjected to reagent significantly to reduce the anesthetized dog myocardial oxygen consumption.
Above experimental result has pointed out compound dragon's blood can pass through coronary artery dilating; suppress the rising of myocardium zymetology CPK, LDH and reduce myocardial oxygen consumption etc.; thereby reduce the heart infarction scope, improve in the many index such as ischemic ST change and demonstrate good protective effect ischemic myocardium; and be dose-effect relationship; simultaneously do not influence hemodynamic indexs such as blood pressure, heart rate, some index is better than isodose compound Salviae Miltiorrhizae.In addition, compound dragon's blood not only suppresses thrombosis, and the effect of thromboembolism again after the thrombosis that forms had thrombolytic effect and prevent thrombolytic, and can improve sticking, dense, with fixed attention, to gather hemorheology unusual, function of promoting blood circulation to disperse blood clots has no side effect.Therefore, compound dragon's blood have very strong resist myocardial ischemia, the function of antithrombotic and blood circulation promoting and blood stasis dispelling.
Claims (5)
1, a kind of medicine for the treatment of cardiovascular disease, it is characterized in that the pharmacodynamic raw materials of making it is made up of Sanguis Draxonis, Radix Notoginseng powder, Borneolum Syntheticum, three's weight proportion is 1: 0.137: 0.0076, wherein Sanguis Draxonis, Radix Notoginseng powder are the purification thing, alcohol soluble substance content 〉=70% of Sanguis Draxonis, the Radix Notoginseng total arasaponins of Radix Notoginseng powder 〉=40%.
2, medicine according to claim 1 is characterized in that alcohol soluble substance content 〉=95% of Sanguis Draxonis, the Radix Notoginseng total arasaponins of Radix Notoginseng powder 〉=50%.
3, medicine according to claim 1 and 2 is characterized in that being tablet, powder, capsule or oral liquid.
4, the preparation method of treatment cardiovascular disease medicine according to claim 1 and 2 is characterized in that having the following steps:
(1) gets the Sanguis Draxonis and the Radix Notoginseng powder of purification, pulverize the back and mix;
(2) mixture with step (1) mixes with the Borneolum Syntheticum of corresponding proportion.
5, the preparation method of medicine according to claim 4, the fineness that it is characterized in that Sanguis Draxonis and Radix Notoginseng powder is more than 800 orders.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031177719A CN1255151C (en) | 2003-04-25 | 2003-04-25 | Compound Longxue scorpion and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB031177719A CN1255151C (en) | 2003-04-25 | 2003-04-25 | Compound Longxue scorpion and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1470268A CN1470268A (en) | 2004-01-28 |
| CN1255151C true CN1255151C (en) | 2006-05-10 |
Family
ID=34152697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB031177719A Expired - Lifetime CN1255151C (en) | 2003-04-25 | 2003-04-25 | Compound Longxue scorpion and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1255151C (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028834A (en) * | 2010-11-23 | 2011-04-27 | 云南云河药业有限公司 | Compound Longxueji preparation and preparation method thereof |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100417387C (en) * | 2004-06-17 | 2008-09-10 | 秦引林 | Compound injection formulation compose dof borneol and pseudo-ginseng total saponin and its preparing method |
| CN100531559C (en) * | 2007-04-12 | 2009-08-26 | 中国热带农业科学院热带生物技术研究所 | Method of artificial cultivation for dragon trees to generate dragon's blood |
| CN101396495B (en) * | 2007-09-26 | 2011-03-30 | 王玉朝 | Traditional Chinese medicine for treating cardiovascular and cerebrovascular disease |
| CN116407518A (en) * | 2021-12-31 | 2023-07-11 | 云南圣科药业有限公司 | Preparation method of pseudo-ginseng dragon's blood capsule |
-
2003
- 2003-04-25 CN CNB031177719A patent/CN1255151C/en not_active Expired - Lifetime
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102028834A (en) * | 2010-11-23 | 2011-04-27 | 云南云河药业有限公司 | Compound Longxueji preparation and preparation method thereof |
| CN102028834B (en) * | 2010-11-23 | 2012-07-04 | 云南云河药业有限公司 | Compound Longxueji preparation and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1470268A (en) | 2004-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100382839C (en) | Chinese-medicinal composition for treating coronary heart disease | |
| CN101843661B (en) | Chinese medicament for treating angina | |
| CN1255151C (en) | Compound Longxue scorpion and preparation method thereof | |
| CN1304769A (en) | Blood-cleaning pill | |
| CN1943620B (en) | Chinese medicine composition for treating cardio-cerabral vascular diseases and its preparing method | |
| CN1060344C (en) | Shumaining preparation for curing ischemic angiocardiopathy or cerebrovascular disease | |
| CN101167838B (en) | Traditional Chinese medicinal preparation for treating coronary heart disease and angina pectoris and its preparing process | |
| CN102204956B (en) | Chinese medicinal composition used at stroke recovery period and preparation method thereof | |
| CN101843660B (en) | Chinese medicament for treating tachycardia | |
| CN101559161B (en) | Application of traditional Chinese medicine composition in preparing medicament for curing tristimania | |
| CN100493543C (en) | Chinese medicine capsule for eliminating drug addiction and its preparation process | |
| CN1686198A (en) | Oral administration medicinal preparation prepared using notoginseng, salvia root and erigeron breviscapus extracts | |
| CN101732637A (en) | Chinese medicament for treating cardiovascular and cerebrovascular diseases | |
| CN102370735B (en) | Application of traditional Chinese medicinal composition in preparation of medicament for treating polycythemia | |
| CN101843644B (en) | Chinese medicament for treating tachycardia | |
| CN111068004A (en) | Traditional Chinese medicine composition for reducing blood pressure and regulating blood fat | |
| CN1318047C (en) | Medicine for preventing and curing cardio cerebral varscular diseases and its preparing method | |
| CN101843672B (en) | Chinese medicament for treating arteriosclerosis | |
| CN101843645B (en) | Chinese medicament for treating tachycardia | |
| CN1548123A (en) | Influenze resisting medicine | |
| CN101843793B (en) | Chinese medicament for treating tachycardia | |
| CN1456330A (en) | Scar eliminating medicine | |
| CN101843835B (en) | Chinese medicament for treating coronary diseases | |
| CN1057008C (en) | Application of theachrome in preparing medicine for viral myocarditis | |
| CN101461875B (en) | Chinese medicinal composition for treating coronary heart disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound Longxue scorpion and preparation method thereof Effective date of registration: 20110623 Granted publication date: 20060510 Pledgee: China Development Bank Co. Yunnan branch Pledgor: Yunnan Yunhe Pharmaceuticals Co.,Ltd. Registration number: 2011990000236 |
|
| C56 | Change in the name or address of the patentee |
Owner name: YUNNAN YUNHE PHARMACEUTICAL CO., LTD. Free format text: FORMER NAME: YUNHE PHARAMCEUTICAL CO., LTD., YUNNAN |
|
| CP03 | Change of name, title or address |
Address after: 661000, 1 Honghe Road, Gejiu City, Honghe Hani and Yi Autonomous Prefecture, Yunnan Province Patentee after: YUNNAN YUNHE PHARMACEUTICALS Inc. Address before: 661000 old Yangshan, Gejiu City, Yunnan Patentee before: Yunnan Yunhe Pharmaceuticals Co.,Ltd. |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20160608 Granted publication date: 20060510 Pledgee: China Development Bank Co. Yunnan branch Pledgor: YUNNAN YUNHE PHARMACEUTICALS INC. Registration number: 2011990000236 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PM01 | Change of the registration of the contract for pledge of patent right |
Change date: 20160608 Registration number: 2011990000236 Pledgor after: YUNNAN YUNHE PHARMACEUTICALS Inc. Pledgor before: Yunnan Yunhe Pharmaceuticals Co.,Ltd. |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound Longxue scorpion and preparation method thereof Effective date of registration: 20160706 Granted publication date: 20060510 Pledgee: Yun energy financing lease (Shanghai) Co.,Ltd. Pledgor: YUNNAN YUNHE PHARMACEUTICALS INC. Registration number: 2016530000011 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20210719 Granted publication date: 20060510 Pledgee: Yun energy financing lease (Shanghai) Co.,Ltd. Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: 2016530000011 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Compound dragon's blood dragon and its preparation method Effective date of registration: 20220224 Granted publication date: 20060510 Pledgee: Gejiu Rural Credit Cooperative Association Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: Y2022530000007 |
|
| PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
| CX01 | Expiry of patent term |
Granted publication date: 20060510 |
|
| CX01 | Expiry of patent term | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20060510 Pledgee: Gejiu Rural Credit Cooperative Association Pledgor: YUNNAN YUNHE PHARMACEUTICALS Inc. Registration number: Y2022530000007 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right |